Sage Rock Capital Management’s Japer Therapeutics Warrants JSPRW Stock Holding History

Sage Rock Capital Management’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-191,300	Closed	-$220K	–	212
2021 Q2	$220K	Hold	191,300	–	–	0.03%	210
2021 Q1	$157K	Hold	191,300	–	–	0.02%	211
2020 Q4	$277K	Sell	191,300 -322,000	-63%	-$404K	0.05%	110
2020 Q3	$606K	Hold	513,300	–	–	0.12%	76
2020 Q2	$513K	Hold	513,300	–	–	0.15%	66
2020 Q1	$334K	Buy	+513,300	New	+$403K	0.14%	57

Other funds holding JSPRW

OCAM

Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Zazove Associates Incline Village, Nevada $1.22B AUM 1.92% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return

Sage Rock Capital Management's JSPRW Position: Q3 2021 in Review

Sage Rock Capital Management sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2021, closing a stake of 191,300 shares — an estimated $220K sold.

Sage Rock Capital Management first reported a position in JSPRW in Q1 2020 and held it in 6 quarters. The position peaked at $606K in Q3 2020. 16 funds tracked by Wall St. Rank hold JSPRW as of Q3 2021.

Sage Rock Capital Management reported no remaining Japer Therapeutics Warrants position as of Q3 2021 after selling out during the quarter.
Sage Rock Capital Management sold 191,300 Japer Therapeutics Warrants shares in Q3 2021, an estimated $220K.
Sage Rock Capital Management first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 6 quarters.
Sage Rock Capital Management's Japer Therapeutics Warrants position peaked at $606K in Q3 2020.
16 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2021.

Based on Sage Rock Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.